MedTrace Logo

Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency

NCT04073017 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2021-05-21

No results posted yet for this study

Summary

This is an open-label phase II basket study evaluating the ability of enterade® to reduce bowel frequency in neuroendocrine tumor (NET) patients with carcinoid syndrome and non-carcinoid syndrome.

Conditions

  • Neuroendocrine Tumor
  • Carcinoid Syndrome

Interventions

DIETARY_SUPPLEMENT

Enterade®

Participants will drink an 8 ounce bottle of Enterade® twice a day for 4 weeks

OTHER

Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)

Ancillary studies

Sponsors & Collaborators

  • Entrinsic Bioscience Inc.

    collaborator INDUSTRY

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • Satya Das, MD · Vanderbilt-Ingram Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-04
Primary Completion
2021-05-18
Completion
2021-05-18

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04073017 on ClinicalTrials.gov